Predictive factors for late normal tissue complications following radiotherapy for breast cancer

Background and purposeRadiotherapy after breast-conserving surgery is commonly applied to reduce recurrence of breast cancer but may cause acute and late side effects. To identify prognostic factors for the development of late toxicity after radiotherapy, we conducted a prospective study of breast cancer patients.Patients and methodsWe assessed late complications of radiotherapy and collected information on epidemiologic factors in a cohort of breast cancer patients who had received radiotherapy after breast-conserving surgery. Among 416 patients with complete follow-up data, the association between possible risk factors and development of late complications was evaluated using multivariate logistic regression analysis.ResultsAfter a median follow-up time of 51 months, 131 (31.4%) patients presented with telangiectasia and 28 (6.7%) patients with fibrosis. We observed a strong association between development of telangiectasia and fibrosis (p < 0.01). Increasing age of the patient was a risk factor for both telangiectasia and fibrosis (p-value for trend <0.01 and 0.03, respectively). Patients with acute skin toxicity (odds ratio (OR) 1.8, 95% confidence interval (CI) 1.0–3.1) were at higher risk to develop telangiectasia. Long-term smoking was associated with a significant increase in risk of telangiectasia compared to non-smokers (OR 2.3, 95% CI 1.2–4.6).ConclusionsOur study revealed several factors other than radiation dose that may predispose to late complications following radiotherapy. Further understanding of differences in response to irradiation may advance individualized treatment and improve cosmetic outcome.

[1]  Hans Svensson,et al.  Dose response and latency for radiation-induced fibrosis, edema, and neuropathy in breast cancer patients. , 2002, International journal of radiation oncology, biology, physics.

[2]  Seegenschmiedt Mh Interdisciplinary documentation of treatment side effects in oncology : Present status and perspectives , 1998 .

[3]  F. Perera,et al.  Carcinogen-DNA adducts in human breast tissue. , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[4]  A. Favier,et al.  Age-dependent DNA repair and cell cycle distribution of human skin fibroblasts in response to UVA irradiation. , 2006, Journal of photochemistry and photobiology. B, Biology.

[5]  J. Peacock,et al.  Why recent studies relating normal tissue response to individual radiosensitivity might have failed and how new studies should be performed. , 2003, International journal of radiation oncology, biology, physics.

[6]  A. Kiltie,et al.  Relationship between in vitro chromosomal radiosensitivity of peripheral blood lymphocytes and the expression of normal tissue damage following radiotherapy for breast cancer. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  A. Hart,et al.  Dose and volume effects on fibrosis after breast conservation therapy. , 1994, International journal of radiation oncology, biology, physics.

[8]  S. Bowden,et al.  Delaying radiotherapy for the delivery of adjuvant chemotherapy in the combined modality treatment of early breast cancer: is it disadvantageous and could combined treatment be the answer? , 2006, Clinical oncology (Royal College of Radiologists (Great Britain)).

[9]  S. Bentzen,et al.  Relationship between early and late normal-tissue injury after postmastectomy radiotherapy. , 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  H. Thierens,et al.  Microsatellite Polymorphisms in DNA Repair Genes XRCC1, XRCC3 and XRCC5 in Patients with Gynecological Tumors: Association with Late Clinical Radiosensitivity and Cancer Incidence , 2005, Radiation research.

[11]  A. Tutt,et al.  Radiobiology of breast cancer. , 2006, Clinical oncology (Royal College of Radiologists (Great Britain)).

[12]  L Collette,et al.  The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC 'boost vs. no boost' trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  J. Chang-Claude,et al.  Personal characteristics, therapy modalities and individual DNA repair capacity as predictive factors of acute skin toxicity in an unselected cohort of breast cancer patients receiving radiotherapy. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  D. Rades,et al.  Late Effects and Cosmetic Results of Conventional Versus Hypofractionated Irradiation in Breast-Conserving Therapy , 2005, Strahlentherapie und Onkologie.

[15]  J. Chang-Claude,et al.  Association between TP53 and p21 genetic polymorphisms and acute side effects of radiotherapy in breast cancer patients , 2006, Breast Cancer Research and Treatment.

[16]  E. Dikomey,et al.  Individual radiosensitivity measured with lymphocytes may be used to predict the risk of fibrosis after radiotherapy for breast cancer. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[17]  R. Gatti The Inherited Basis of Human Radiosensitivity , 2001, Acta oncologica.

[18]  J. Yarnold,et al.  The influence of breast size on late radiation effects and association with radiotherapy dose inhomogeneity. , 1994, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[19]  D. Moore Drug-Induced Cutaneous Photosensitivity , 2002 .

[20]  S. McDonald,et al.  A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. , 1995, International journal of radiation oncology, biology, physics.

[21]  S. Bentzen,et al.  Early and late normal tissue injury after postmastectomy radiotherapy. , 1993, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[22]  J. Denekamp,et al.  Timescale of evolution of late radiation injury after postoperative radiotherapy of breast cancer patients. , 2000, International journal of radiation oncology, biology, physics.

[23]  C. Terhaard,et al.  Radiotherapy in T1 laryngeal cancer: prognostic factors for locoregional control and survival, uni- and multivariate analysis. , 1991, International journal of radiation oncology, biology, physics.

[24]  M. Dewhirst,et al.  Radiation-induced hypoxia may perpetuate late normal tissue injury. , 2001, International journal of radiation oncology, biology, physics.

[25]  D. Moore Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management. , 2002, Drug safety.

[26]  J Nyman,et al.  Prognostic factors for acute and late skin reactions in radiotherapy patients. , 1996, International journal of radiation oncology, biology, physics.

[27]  H. Thames,et al.  Fractionation sensitivity of a functional endpoint: impaired shoulder movement after post-mastectomy radiotherapy. , 1989, International journal of radiation oncology, biology, physics.

[28]  Jong-Hyeon Jeong,et al.  Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. , 2002, The New England journal of medicine.

[29]  Bentzen,et al.  Patient-to-Patient Variability in the Expression of Radiation-Induced Normal Tissue Injury. , 1994, Seminars in radiation oncology.

[30]  C. Arlett,et al.  Four radiation hypersensitivity cases and their implications for clinical radiotherapy. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[31]  J. Chang-Claude,et al.  Studies on radiosensitivity from an epidemiological point of view - overview of methods and results. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[32]  J. Chang-Claude,et al.  Association between Polymorphisms in the DNA Repair Genes, XRCC1, APE1, and XPD and Acute Side Effects of Radiotherapy in Breast Cancer Patients , 2005, Clinical Cancer Research.

[33]  A. Seluanov,et al.  Making ends meet in old age: DSB repair and aging , 2005, Mechanisms of Ageing and Development.

[34]  D. Cox,et al.  ATM haplotypes and cellular response to DNA damage: association with breast cancer risk and clinical radiosensitivity. , 2003, Cancer research.

[35]  F. Böhler,et al.  [Hypertension as risk factor for increased rate of side effects in the framework of breast carcinoma irradiation]. , 1992, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

[36]  D. Cox,et al.  Polymorphisms in the DNA repair gene XRCC1, breast cancer risk, and response to radiotherapy. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[37]  S. Dische,et al.  Smoking and mucosal reactions to radiotherapy. , 1990, The British journal of radiology.

[38]  Frederick W. Alt,et al.  DNA Repair, Genome Stability, and Aging , 2005, Cell.

[39]  H. Fukuda,et al.  European Organization for Research and Treatment of Cancer (EORTC) and International Society for Cutaneous Lymphoma (ISCL) consensus recommendations for the management of cutaneous B-cell lymphomas Blood 2008; 112(5):1600-9 , 2022 .

[40]  B. Green,et al.  Carcinogen–DNA adducts in human breast epithelial cells , 2002, Environmental and molecular mutagenesis.

[41]  J E Mortimer,et al.  Factors influencing cosmetic results after conservation therapy for breast cancer. , 1995, International journal of radiation oncology, biology, physics.

[42]  H. Bartelink,et al.  The influence of the boost in breast-conserving therapy on cosmetic outcome in the EORTC "boost versus no boost" trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer. , 1999, International journal of radiation oncology, biology, physics.

[43]  Manuel A. R. Ferreira,et al.  Cytokine expression in allergic inflammation: systematic review of in vivo challenge studies. , 2003, Mediators of inflammation.

[44]  M. Seegenschmiedt Interdisciplinary documentation of treatment side effects in oncology. Present status and perspectives. , 1998, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].